Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report.

#1898

Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).

Aim(s): A 39-year-old male with NEN G2 of unknown primary site with metastases to liver and bones.

Materials and methods: Since May 2011 patient with abdominal symptoms. CT revealed enlarged liver with metastases. In June 2011 consultation of specimens from metastatic lesions in liver (from laparoscopy) confirmed the diagnosis of NEN G2 Ki-67 uptil 20%. NEN markers and another hormones were in reference values. 68Ga-DOTA-TATE PET/CT scan confirmed the presence of changes with increased expression of somatostatin receptors (SSTR) in the liver and in the skeletal system. Since June 2011 patient has begun treatment with a long-acting somatostatin analogues (SSA). Between 08.2011 and 08.2012 patient received 6 cycles of 90Y/177Lu DOTA-TATE (800 mCi). In April 2013, PET/CT with gallium showed significant regression. In April 2014 PET/CT with gallium showed new foci of increased tracer uptake. In 09.2014 treatment with CAPTEM combined with SSA was commenced. Stereotactic radiosurgery therapy of metastatic changes in brain was carried out (10.2014), but in performed chest CT progression of disease was identified. Between 07.2015 and 02.2016, 4 further cycles of 90Y/177Lu DOTA-TATE treatment were administered (800 mC).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strzelczyk J, Poczkaj K, Rosiek V, Kos-Kudła B,

Keywords: neuroendocrine neoplasm, metastases, radionuclide therapy,